PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that it received the U.S. Food and Drug Administration (FDA) approval for the Company's ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain manag
Biotechnology, Pharmaceuticals
2025-08-11 9:49 AM EDT | PharmaTher Holdings Ltd.
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
Boca Raton, Florida--(Newsfile Corp. - August 11, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $3 million of pre-funded and common warrants. The entire transaction has been priced at the market
Biotechnology, Pharmaceuticals
2025-08-11 7:30 AM EDT | Entero Therapeutics, Inc.
BioHarvest Sciences Reports Second Quarter 2025 Financial Results
Rehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights All figures stated in this news release are in U.S. dollars unless stat
Biotechnology, Pharmaceuticals, Health
2025-08-11 7:30 AM EDT | BioHarvest Sciences Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2026 fiscal year will be released on Thursday, August 14, 2025. Elite's management will host a live conference call on Friday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results
Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-08 4:30 PM EDT | Elite Pharmaceuticals, Inc.
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key second quarter and 2025 year-to-date corporate highlights include: KIO-104 Initiated
Biotechnology, Pharmaceuticals
2025-08-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Maxwell Biosciences Announces Closing of $20M Financing Round
Austin, Texas--(Newsfile Corp. - August 7, 2025) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today announced the closing of its $20 million financing round. The funds will support Maxwell's upcoming FDA clinical trials and advance AI-driven R&D. The funds will also expand commercialization in multiple other industries in which nontoxic antiseptics are highly valued, such as cosmetics, clean
Biotechnology, Pharmaceuticals
2025-08-07 9:30 AM EDT | Maxwell Biosciences, Inc.
TempraMed Partners with the Diabetes Education & Camping Association of the USA (DECA), Supporting Safe Insulin Storage for Children at Diabetes Camps Across the United States
Sammamish, Washington--(Newsfile Corp. - August 7, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is proud to announce a new partnership with the Diabetes Education & Camping Association (DECA) by providing VIVI Cap devices to diabetes camps across the United States. As part of this partnership, TempraMed is providing these critical temperature-sensitive s
Technology, Biotechnology, Pharmaceuticals, Health
2025-08-07 7:00 AM EDT | TempraMed Technologies Ltd
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Encinitas, California--(Newsfile Corp. - August 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its President and CEO, Brian M. Strem, Ph.D., will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Presentation Details
Biotechnology, Pharmaceuticals
2025-08-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Medexus Schedules First Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, August 13, 2025 to discuss Medexus's results for its first fiscal quarter ended June 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on August 12, 2025. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-05 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Republic Technologies Partners with BitGo to Safeguard Ethereum Operations
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (the "Company" or "Republic") is pleased to announce a strategic partnership with BitGo Trust Company Inc., the leading infrastructure provider of digital asset solutions, to safeguard its Ethereum (ETH) infrastructure operations and digital asset treasury with institutional-grade security and regulatory compliance. BitGo is the leading digital asset infrastructure
Technology, Pharmaceuticals, Health
2025-08-05 8:00 AM EDT | Republic Technologies Inc.
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the US Centers for Medicare & Medicaid Services (CMS) has approved New Technology Add-On Payment (NTAP) reimbursement for eligible cases involving the use of GRAFAPEX™ (treosulfan) for Injection for CMS's fiscal year 2026, which runs from October 1, 2025 to September 30, 2026.* The NTAP program is designed to provide temporar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-05 7:00 AM EDT | Medexus Pharmaceuticals Inc.
BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m. Eastern Time
Rehovot, Israel--(Newsfile Corp. - August 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the second quarter ended June 30, 2025 before market open on Monday, August 11, 2025. Management will host an investor conference call and webcast at 8:00 a
Biotechnology, Pharmaceuticals, Health
2025-08-04 8:30 AM EDT | BioHarvest Sciences Inc.
Hemostemix Increases Previously Closed Private Placement to $3,000,000
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Further to its press release dated July 24, 2025, Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") wishes to provide an update regarding its previously closed non-brokered private placement (the "Offering"). The Company confirms that, following the receipt of additional subscriptions not included in the original Offering which closed on July 23, 2025, the size of the Offering
Biotechnology, Pharmaceuticals, Health
2025-07-31 5:53 PM EDT | Hemostemix Inc.
Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to highlight a groundbreaking research article published in Cells on June 29, 2025, by Fraser C. Henderson Sr. and Ms. Kelly Tuchman, exploring how a combination of the patient's own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may s
Biotechnology, Pharmaceuticals, Health
2025-07-31 2:49 PM EDT | Hemostemix Inc.
Unbuzzd Wellness Commences Reg D Capital Raise Campaign
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2025) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM — the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms — today announced the launch of its previously announced Regulation D 506(c) offering to raise up to US$5.0 million to fund growth and establish a path to a possible in
2025-07-31 7:00 AM EDT | Unbuzzd Wellness Inc.
Republic Technologies Leverages Kraken to Advance Ethereum Infrastructure
Vancouver, British Columbia--(Newsfile Corp. - July 29, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM) ("Republic" or the "Company") is pleased to announce that it has integrated with Kraken, one of the world's leading digital asset exchanges, to support the execution and growth of Republic's infrastructure operations. Founded in 2011, Kraken is a global leader in digital asset trading and infrastructure, serving institutional clients in over 190 countries and regulat
Technology, Pharmaceuticals, Health
2025-07-29 8:00 AM EDT | Republic Technologies Inc.
Theralase(R) Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On clo
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-07-28 7:00 AM EDT | Theralase Technologies Inc.
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disea
Biotechnology, Pharmaceuticals
2025-07-28 7:00 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, havin
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-07-25 3:04 PM EDT | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that patho
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-07-25 12:36 PM EDT | Phio Pharmaceuticals Corp.